Information intended for UK healthcare professionals only.  These promotional videos have been funded by Bristol Myers Squibb on behalf of the BMS − Pfizer Alliance and developed in conjunction with Guidelines. See bottom of the page for full disclaimer.

View Eliquis (apixaban) prescribing and adverse event reporting information

In these videos Dr Yassir Javaid (Cardiovascular and Diabetes Lead Nene CCG; Primary Care Cardiovascular Lead, East Midlands Clinical Network; RCGP Clinical Adviser for Cardiology) and Dr Edward Middleton (Consultant in Acute Medicine, Hull Royal Infirmary) summarise the main messages covered in the live webinar ’Modern management of venous thromboembolism in primary care’, broadcast on 3 November 2020.

Diagnosis and management of venous thromboembolism in primary care

Appropriate dosing for patients with venous thromboembolism

Modern management of venous thromboembolism in primary care: Q&A session

Diagnosis and management of venous thromboembolism in primary care

Appropriate dosing for patients with venous thromboembolism

Modern management of venous thromboembolism in primary care: Q&A session

Adverse events should be reported. Reporting forms and information can be found at: UK – www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store Adverse events should also be reported to Bristol-Myers Squibb via medical.information@bms.com or 0800 731 1736 (UK)

These promotional videos have been funded by Bristol Myers Squibb on behalf of the BMS − Pfizer Alliance and developed in conjunction with Guidelines.  Bristol Myers Squibb has reviewed the scope of the videos, chosen and commissioned the speakers, and approved all materials related to the videos. Bristol Myers Squibb has paid the speakers honoraria. The views and opinions of the speakers are not necessarily those of the BMS – Pfizer Alliance, or of Guidelines, its publisher, advisers, or advertisers. No part of these videos may be reproduced in any form without the permission of the publisher.

432-GB-2100016

Date of preparation: February 2021